Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc is experiencing a positive outlook due to its compelling clinical results, particularly with the GRI-0621 program, which has demonstrated improvements in serum biomarkers related to fibrosis and positive lung function data without decline during its 12-week treatment period. The company's current valuation appears attractive, with significant upside potential highlighted by net present value (NPV) analyses that suggest a favorable investment opportunity. Additionally, the ongoing development of GRI-0803 as a novel oral agonist for autoimmune disorders further underlines GRI Bio's capacity to contribute innovative therapies in a market with high unmet needs.

Bears say

GRI Bio Inc reported a net loss of $3.4 million with an earnings per share (EPS) of $(1.28), which was worse than both internal estimates and market consensus, indicating potential financial instability. The company faces significant risks concerning liquidity and balance sheet management, compounded by the uncertain outcomes of clinical trials and the regulatory approval process for its product candidates, GRI-0621 and GRI-0803. Furthermore, the lengthy development and commercialization timelines for its therapies present ongoing challenges, overshadowing the substantial market potential estimated at approximately one billion dollars.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.